Highland Therapeutics Announces Positive Interim Results From Phase I/II Study
of HLD-200 in ADHD Patients
TORONTO, Oct. 3, 2013
TORONTO, Oct. 3, 2013 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"),
a specialty pharmaceutical company leveraging its proprietary technologies to
optimize the delivery of previously approved drug products, today announced
that its wholly owned subsidiary has generated positive interim Phase I/II
results from an ongoing study of HLD-200 - a novel formulation of
methylphenidate being developed to treat the symptoms associated with
Attention-Deficit/Hyperactivity Disorder (ADHD).
The study, "A Phase I/II, Single Center, Single-Treatment, Open-Label,
Adaptive Clinical Trial Design Examining the Pharmacokinetic Effects of up to
Two Separate HLD-200 Modified Release Formulations of Methylphenidate in
Adolescent and Pediatric Subjects with Attention-Deficit Hyperactivity
Disorder", is expected to be completed in the fourth quarter of 2013.
Based on an interim analysis of data from adolescent patients, the study
demonstrated that the active pharmaceutical ingredient (API), methylphenidate,
was consistently delivered in a manner that allows for dosing of HLD-200 prior
to bedtime, with the objective of controlling the symptoms of ADHD immediately
upon wakening. Further, a comparative analysis of the pharmacokinetic (PK)
profiles suggests that HLD-200 could have an extended duration of effect when
compared to other once-daily methylphenidate medications. Notably, patients
enrolled in the study did not report any significant adverse events, which
suggests that HLD-200 could potentially have a better safety profile than
other available medications to treat ADHD. Methylphenidate is currently sold
under the brand name Concerta by Janssen Pharmaceuticals, Inc. (a Johnson &
Johnson company) and Ritalin/Ritalin LA by Novartis Pharmaceuticals
"These results, which are the first we have generated in adolescent patients,
confirm that Highland's drug delivery platform is extremely reliable and
delivers the API consistently and reproducibly across patients. Moreover, the
drug release does not appear to be affected by the patient's age or
differences in physiology between adolescent patients and healthy adult
volunteers," said David Lickrish, President and CEO of Highland Therapeutics
Inc. "We are excited to see that our proprietary technology has the potential
to improve the lives of patients and their families, who struggle with the
uncontrolled symptoms of ADHD during the early morning routine. Highland was
founded on the belief that we could address this unmet medical need, providing
a solution for all families who struggle during this busy and important time
According to an independent survey sponsored by Highland, the vast majority of
families report challenges with the uncontrolled symptoms of ADHD during the
early morning routine, with 55% of these characterizing the level of
impairment as "severe" or "moderate-to-severe". This impairment has a
significant impact on the quality of life for the patient and their families.
Many physicians advocate that a good start to the day for patients with ADHD
could result in positive amplifying effects, whereas the opposite experience
often results in negative, cascading effects.
Dr. Bev Incledon, Senior Vice President, Research & Development said: "The
market for ADHD treatments has grown substantially over the past 10 years and
consumers today have a number of different options to choose from, yet a
significant unmet medical need remains. Our goal was to develop a medication
that would address this need. Based on the strength of the results achieved to
date, we believe that our drug candidates, both HLD-200 (methylphenidate) and
HLD-100 (amphetamine), are likely to work exceptionally well in our target
markets. Prior to year-end, we intend to request a meeting with the U.S. Food
& Drug Administration (FDA) to discuss what steps may be necessary in order to
obtain approval for this important, and much-needed, medication."
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is a specialty pharmaceutical company that, through
its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is
leveraging its proprietary technologies to optimize the delivery of previously
approved drug products. The Company's lead products, HLD-100 and HLD-200, are
novel formulations of the psychostimulants (amphetamine and methylphenidate,
respectively) used to treat ADHD and are being developed to address a
prevalent unmet medical need in the treatment of the disease - the lack of
symptom control during the early morning routine. The clinically meaningful
benefits of Highland's approach are targeted at helping ADHD patients and
their families improve the quality of their lives.
Highland Therapeutics Inc. is a client of MaRS Discovery District's Life
Sciences and Healthcare practice, which provides advisory services and support
to help Ontario life sciences companies grow and commercialize their
This press release contains forward-looking information, which reflects
Highland's current expectations regarding future events. Forward-looking
information is based on a number of assumptions and is subject to a number of
risks and uncertainties, many of which are beyond Highland's control that
could cause actual results and events to differ materially from those that are
disclosed in or implied by such forward-looking information. These
forward-looking statements are made as of the date of this press release and,
except as expressly required by applicable law, Highland assumes no obligation
to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.
SOURCE Highland Therapeutics Inc.
please contact Nelson F. Isabel at (647) 260-7875.
Press spacebar to pause and continue. Press esc to stop.